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Abstract: The study sought to test the hypothesis that co-administration of SNAP and cysteine or 
CapSNO and cysteine in normoglycaemic rats may further reduce glucose tolerance. An oral glucose 
tolerance  was  carried  out  and  the  plasma  nitrite  concentrations  were  measured  and  taken  as  the 
biochemical  markers  of  in  vivo  NO  formation.  The  results  showed  blood  glucose  levels  were 
significantly elevated at fasting (F2) and 2.5 h time intervals of the oral glucose tolerance test on 
administration of SNAP at 12.5 mg kg
-1 body weight (BW) or CapSNO at 12.5 mg kg
-1 BW compared 
to captopril (12.5 mg kg
-1 BW, control). Co-administration of SNAP and cysteine (30 mg kg
-1 BW), or 
CapSNO and cysteine enhanced the postprandial hyperglycemic effect at the 2.0 or 2.5 h time intervals 
compared with the administration of SNAP or CapSNO only (p<0.05). The increased postprandial 
blood glucose concentration was associated with a significant elevation of NO produced from CapSNO 
and SNAP as assessed by plasma nitrite concentration. Co-administration of cysteine and CapSNO 
caused a significant increase in total nitrite concentration compared with the administration of only 
CapSNO (52.63±2.69 µM vs 32.36±3.66 µM, p = 0.03). The results suggested that in normoglycaemic 
rats, NO released from SNAP and CapSNO caused a significant hyperglycaemic effect (p<0.05). This 
effect was enhanced by cysteine as evidenced by the observed increased total nitrite concentration 
resulting in exacerbation of the impaired glucose tolerance. 
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INTRODUCTION 
 
  Nitric oxide (NO) is a ubiquitous molecule that is 
implicated  in  many  physiological  processes.  It  is 
capable  of  interacting  with  many  cellular  targets, 
including heme and non-heme iron, thiols, oxygen and 
superoxide anions
[1].  Reactions  with these targets can 
result in physiological effects such as the inactivation of 
guanylate  cyclase  or  the  S-nitrosylation  of  proteins 
leading to signaling functions
[2,3]. The reaction of NO 
with  thiols  results  in  the  formation  of  S-nitrosothiols 
(RSNOs) which act as storage and transport molecules 
of  NO
[4].  S-nitrosothiols  are  present  at  micro-molar 
concentrations  in  the  body  and  are  more  stable  than 
NO. Some of these compounds are unable to permeate 
cell  membranes  due  to  their  hydrophilic  nature
[5]. 
However  studies  have  shown  that  S-nitroso-captopril 
(CapSNO) is able to cross cell membranes
[6]. The rate 
of  decomposition  of  RSNOs  is  increased  in  the 
presence of reduced metal ions
[7], ascorbic acid
[8] and 
thiols such as glutathione
[9] and cysteine
[10].  
  S-nitroso-N-acetylpenicillamine  (SNAP)  and 
CapSNO are examples of synthetic RSNOs which have 
been  used  extensively  in  research.  S-nitroso-N-
acetylpenicillamine is one of the most commonly used 
S-nitrosothiols  in  experimental  setting,  however  NO 
released  from  SNAP  is  unpredictable  due  to  its 
sensitivity to Cu (I) ions
[11]. It has been shown to have 
powerful vasodilatory effect and antiplatelet activity in 
the  cardiovascular  system
[4]  and  was  found  to Am. J. Biochem. & Biotech., 4 (3): 265-272, 2008 
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significantly  reduce  mean  arterial  blood  pressure  in 
animals
[12]. However, its use as an antiplatelet agent is 
limited  by  its  intense  vasodilatory  and  hence 
hypotensive effects. The half-life of SNAP is 1.15 h
[13] 
and  decomposition  of  SNAP  involves  the  hemolytic 
cleavage of the S-NO bond with the release of NO and 
the formation of an alkyl thiyl radical followed by the 
combination  of  two  thiyl  radicals  to  give  the 
corresponding disulfide
[14].  
  S-nitroso-captopril is a S-nitroso derivative and it 
is a hybrid compound of both captopril and NO
[15]. As a 
unique  compound,  it  has  properties  of  both  a  direct 
nitrovasodilator and an angiotensin converting enzyme 
(ACE) inhibitor and is not cross-tolerant with gylceryl 
trinitrate (GTN)
[16]. S-nitroso-captopril is water soluble 
and relatively stable in physiological solution having a 
half-life of 2.5 h. It activates soluble guanylate cyclase 
in  smooth  muscle  and  platelets,  leading  to  direct, 
endothelium-independent smooth muscle relaxation and 
inhibition of platelet aggregation, respectively
[16]. These 
properties  of  CapSNO  make  it  a  very  interesting 
pharmacological agent.  
  Experimental  evidence  from  animal  studies 
suggested that SNAP had a beneficial effect of reducing 
blood  pressure,  however  this  was  associated  with 
decreased glucose tolerance
[12]. We sought to test the 
hypothesis  that  co-administration  of  CapSNO  and 
cysteine or SNAP and cysteine in an animal model may 
further  deteriorate  glycemic  control.  Therefore  the 
study investigates the effects of CapSNO, or SNAP co-
administered  with  cysteine  on  blood  glucose 
concentration  in  rats.  The  total  plasma  nitrite 
concentration was measured to determine whether the 
mode of action is via the release of NO. 
 
MATERIALS AND METHODS 
 
Animal care-experimental design: Rats were obtained 
from  the  Basic  Medical  Sciences  Animal  House, 
University of the West Indies, Mona. Healthy male and 
female Wistar mixed breed rats were used within the 
weight range of 250-350 grams. The rats were kept in 
separate cages according to their sex to eliminate the 
possibility   of   impregnation.   The  rats were fed a 
daily  diet      of      Purina  Lab  Chow  and  water 
administered ad libitum. All procedures were approved 
by and conducted in accordance with the guidelines of 
The University of the West Indies Animal Care and Use 
Committee.  
Sample preparation: A dosage of 12.5 mg kg
-1 BW of 
captopril,  CapSNO,  SNAP  and  30  mg  kg
-1  BW  of 
cysteine  were  used  for  the  analysis.  Saline  (0.4  mL, 
0.9%  NaCl)  was  used  to  dissolve  captopril  and 
CapSNO  and  dimethyl  sulfoxide  [(DMSO,  0.4  mL, 
50%); Sigma Chemical Co, St. Louis, MO, USA] was 
used to dissolve SNAP just before the beginning of the 
analysis. The solution was then administered into the 
tail  vein  of  the  rat  immediately  after  the  first  blood 
sample was obtained for analysis. 
 
Oral Glucose Tolerance Test (OGTT): Oral glucose 
tolerance (OGTT) was carried out using an automated 
method.  The  glucometer  (Miles  Inc.  Diagnostics 
Division, Indiana, USA) was calibrated with standard 
solutions before use to allow for optimum performance. 
The test was carried out on rats to determine the effect 
of  captopril,  SNAP  (Sigma  Chemical  Co,  St.  Louis, 
MO,  USA),  CapSNO,  cysteine,  CapSNO  co-
administered with cysteine and SNAP co-administered 
with cysteine, via intravenous administration on blood 
glucose  levels  in  normoglycemic  rats.  S-nitroso-
captopril  was  synthesized  as  previously  described
[17]. 
Captopril, CapSNO and SNAP were administered at a 
dosage of 12.5 mg kg
-1 body weight (BW) and cysteine 
was administered at a dosage of 30 mg kg
-1 BW.
 Rats 
were  fasted  for  approximately  15  h,  during  this  time 
only  water  was  given  ad  libitum.  A  fasting  blood 
sample at time (F1)  was obtained from the rat’s tail, 
immediately after which CapSNO, SNAP or captopril 
was  administered  via  the  intravenous  route.  Fasting 
blood  samples  were  taken  at  F1,  F2  and  0  h.  In 
experiments  involving  the  co-administration  of 
CapSNO  and  cysteine  or  SNAP  and  cysteine,  the 
mixture was also administered after the blood sample  
was    taken  at  F1.  Immediately  after  the  1  h  fasting 
sample was taken (0 h), a glucose load at a dosage of 
1.75  g  kg
-1  BW  was  then  administered  orally,  after 
which postprandial blood samples were taken at 0.5 h 
intervals for a further 2.5 h.  
 
Total  nitrite  analysis:  Total  nitrite  (NO2
-) 
concentration  was  determined  using  a  colourimetric 
non-enzymatic  nitric  oxide  assay  kit  (Oxford 
Biomedical) which incorporates the use of the Greiss 
reagent.  A dosage of 12.5 mg kg
-1 BW of captopril, 
CapSNO, SNAP and 30 mg kg
-1 BW of cysteine were 
administered via i.v. into the tail vein of the rat. After 
30 min the rat was anaesthetized using a mild anesthetic 
and dissection carried out. Whole blood was carefully 
obtained from the heart and was placed in labeled 3 mL 
purple top K3-vacutainers. Centrifugation then followed 
at 3500 rpm for 10 min. Plasma (1 mL) was placed in 
labeled eppendorf tubes and stored at -80ºC for further Am. J. Biochem. & Biotech., 4 (3): 265-272, 2008 
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use.  The  rat  was  then  disposed  of  according  to 
regulations stipulated in the animal care protocol. 
 
Statistics: Each point was expressed as mean±standard 
error  or  the  mean  (SEM).  For  OGTT  a  minimum 
sample  size  of  9  rats  was  used  to  carry  out  the 
investigation. Blood samples were taken in duplicates 
for each time interval. For the total nitrite analysis, each 
compound was assayed in duplicates. In addition, each 
experiment  was  repeated  three  times.  The  average 
absorbance was determined from a standard curve and 
the  necessary  calculations  done.  The  values  were 
compared using Student’s t-test. p-values less than 0.05 
were considered to be significant in all cases. 
 
RESULTS AND DISCUSSION 
 
  S-nitroso-captopril  and  SNAP  had  significant 
effects on the fasting blood glucose concentrations with 
values  at  F2  of  5.11±0.08  and  5.91±0.11  mmol  L
-1 
(p<0.05)  respectively,  compared  with  3.80±0.23  and 
4.14±0.11  mmol  L
-1  in  rats  treated  with  saline  and 
captopril  respectively  (Fig.  1).  Rats  treated  with 
CapSNO  had  the  highest  postprandial  blood  glucose 
concentration of 6.81±0.23 mmol L
-1 at the 0.5 h time 
point  compared  with  6.31±0.20  and  5.92±0.14  mmol 
L
-1 in rats treated with SNAP and captoril respectively. 
These  values  were  significantly  different  from  the 
postprandial blood glucose concentration of rats treated 
with saline at the same time point (4.58±0.29 mmol L
-1, 
p<0.00001). There was a gradual decline in mean blood 
glucose concentrations from peak values in rats treated 
with CapSNO, SNAP or captopril. The blood glucose 
concentrations in rats which were treated with SNAP or 
CapSNO  were  5.46±0.12  and  5.26±0.05  mmol  L
-1 
respectively  at  the  2.5  h  time  point  compared  with 
4.63±0.12  mmol  L
-1  in  rats  treated  with  captopril 
(p<0.05).  
  Rats treated with cysteine only and CapSNO and 
cysteine  showed  lower  postprandial  blood  glucose 
concentrations at the 0.5 h time point (6.24±0.29 and 
6.10±0.15  mmol  L
-1  respectively,  Fig.  2)  compared 
with rats treated with CapSNO only (6.81±0.23 mmol 
L
-1).  The  blood  glucose  concentration  in  rats  treated 
with CapSNO and cysteine decreased slightly at the 1.0 
h time point and then gradually increased to peak value 
at the 2.5 h time point. This trend is in contrast to the 
postprandial blood glucose concentration in rats treated 
with cysteine only which increased slightly at the 1.0 h 
time point and then gradually decreased with the lowest  
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Fig. 1: Effect  of  captopril,  SNAP  and  CapSNO  on 
blood glucose concentration 
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Fig. 2:  The  Effect  of  CapSNO  co-administered  with 
cysteine on Blood Glucose Concentration Am. J. Biochem. & Biotech., 4 (3): 265-272, 2008 
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Fig. 3: The  Effect  of  SNAP  co-administered  with 
cysteine on Blood Glucose Concentration 
 
value  at  the  2.5  h  time  point.  There  was  significant 
difference in postprandial blood glucose concentrations 
at the 2.0 and 2.5 h time points in rats co-administered 
with CapSNO and cysteine giving values of 6.40±0.25 
and  6.47±0.26  mmol  L
-1  respectively  compared  with 
those  treated  with  only  CapSNO  with  values  of 
5.18±0.31 mmol L
-1 (2.0 h) and 5.46±0.11 mmol L
-1 
(2.5 h, p<0.05). There were also significant differences 
in  postprandial  blood  glucose  concentrations  in  rats 
treated with CapSNO observed at the 2.5 h time points 
and those treated with cysteine (4.55±0.13, p = 0.003).  
  The postprandial blood glucose concentrations of 
rats treated with SNAP, or cysteine were slightly higher 
than  those  of  rats  co-administered  with  SNAP  and 
cysteine at the 0.5 and 1.0 h time points (Fig. 3). There 
was a gradual decrease thereafter in the blood glucose 
concentrations in rats treated with SNAP or cysteine, 
with the lowest values observed at the 2.5 h time points 
(i.e., 5.26±0.05 and 4.55±0.13 mmol L
-1 respectively). 
This is in contrast with the postprandial blood glucose 
concentration  in  rats  treated  with  both  SNAP  and 
cysteine which showed an increase to a peak value at 
the  2.0  h  time  point  (6.25±0.24  mmol  L
-1)  and  then 
decreased    slightly    at    the    2.5    h    time    point 
(6.04±0.17   mmol  L
-1,  p<0.05). Therefore, significant  
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Fig. 4: The Effect of CapSNO, SNAP and Captopril on 
Total Nitrite Concentration 
 
differences in postprandial blood glucose concentration 
were  observed  between  rats  treated  with  cysteine  or 
SNAP compared with those co-administered with both 
SNAP and cysteine at the 2.0 h (p<0.05) and 2.5 h time 
points (p<0.05). 
  The  total  nitrite  concentration  in  rats  that  were 
administered  with  saline  was  23.61±3.75  µM,  which 
represented  endogenous  nitrite  production  (Fig.  4). 
Captopril-treated rats gave a total nitrite concentration 
of  20.90±3.45  µM.  On  the  other  hand  CapSNO 
(32.36±3.66 µM) and SNAP (84.57±5.68 µM) treated 
rats  showed  a  significant  increase  in  the  total  nitrite 
concentration when compared with either captopril or 
saline treated rats (p<0.05). In addition rats that were 
administered  with  SNAP  showed  a  more  significant 
increase in total nitrite concentration than rats treated 
with CapSNO (p = 0.02).  
  The data showed that there was an increase in the 
total  nitrite  concentration  to  52.63±2.69  µM  for 
CapSNO  and  cysteine-treated  rats  compared  to  rats 
administered with only CapSNO (32.36±3.66 µM, p = 
0.03, Fig. 5).  
  In  this  study  the  nitric  oxide  donors  SNAP  and 
CapSNO  caused  impaired  glucose  tolerance  in 
normoglycemic  rats  by  increasing  fasting  and  even 
more  significantly  postprandial  blood  glucose 
concentrations. However, the major finding of the study 
is that the co-administration of cysteine and SNAP, or 
cysteine  and  CapSNO  in  the  rats  increased  the 
hyperglycemic effect at the 2.0 and 2.5 h time points, 
resulting  in  further  deterioration  of  glycemic  control. 
The    post-prandial    blood    glucose  concentration  at 
these two   time   points  are  significantly  higher  than  
those   obtained   upon  administration  only   SNAP   or  Am. J. Biochem. & Biotech., 4 (3): 265-272, 2008 
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Fig. 5: The  effect  of  CapSNO  or  SNAP  co-
administered  with  Cysteine  on  Total  Nitrite 
Concentration 
 
CapSNO only. The hyperglycemic effect of SNAP and 
CapSNO  are  in  agreement  with  previous  reports  by 
McGrowder  and  colleagues  who  showed  that  GSNO 
and  SNAP  increased  postprandial  blood  glucose 
concentration  in  normoglycemic  dogs.  These 
investigators  showed  decreased  postprandial  plasma 
insulin  concentrations
[12]  and  increased  plasma 
glucagon  concentration
[18].  The  cysteine  administered 
deteriorates the decreased glucose tolerance by the NO 
donors and may delay or decrease insulin response to a 
glucose  challenge  in  an  animal  model,  thereby 
prolonged the postprandial hyperglycemia
[12]. 
  S-nitroso-N-acetylpenicillamine  and  CapSNO  are 
primary and tertiary RSNOs respectively, however due 
to the close molecular weight of the compounds; there 
would not be any significant difference in the rate of 
diffusion  through  the  vascular  system.  S-nitroso-
captopril having a more stable structure would be more 
resistant  to  decomposition  when  compared  with 
SNAP
[9].  The  ability  of  SNAP  to  permeate  cell 
membrane has not been fully elucidated, however it has 
been  shown  that  CapSNO  is  able  to  permeate  these 
barriers
[6]. The increase in blood glucose concentrations 
was  more  significant  in  SNAP-treated  rats  when 
compared  with  CapSNO  treated  rats.  The 
hyperglycemic  effect  observed  may  be  linked  to  the 
potency  of  SNAP  as  well  as  the  ease  at  which  this 
compound  is  able  to  decompose  in  vivo  by  a 
mechanism  that  is  facilitated  by  endogenous  reduced 
metal ions and thiols. Nitric oxide released from SNAP 
and  CapSNO  may  be  toxic  at  non-  physiological 
concentration where it appears to function as a cellular 
effector  molecule  that  mediates  both  cytostatic  and 
cytotoxic effects
[16]. Previous evidence have indicated 
that  pancreatic  islet  cells  exposed  to  the  NO-donor 
streptozotocin  caused  lasting,  damage  to  the  ￿-cells, 
characterized  by  a  persistent  impairment  in  glucose 
metabolism  and  a  defective  insulin  response
[19].  The 
mechanism  by  which  streptozotocin  affects  the 
pancreas  could  account  for  the  hyperglycemic  effect 
observed in the rats treated with SNAP or CapSNO. 
  S-nitrosocaptopril  and  SNAP  were  used  in  our 
experiments because these two compounds are the most 
typical and stable S-nitrosothiols and have been widely 
used in the biological research on NO. The interactions 
of  NO  with  sulfhydryl-containing  molecules  and 
enzymes  have  gained  considerable  importance
[5,6].  In 
many  biological  systems,  S-nitrosylation  reactions, 
transferring NO from CapSNO and SNAP to a protein 
sulfhydryl  group,  affect  protein  function.  The  blood 
glucose  concentrations  for  cysteine  and  SNAP  or 
cysteine  co-administered  with  CapSNO-treated  rats 
were well outside of the normal limits at the 2.0 and 2.5 
h time points and were significantly elevated above that 
of  their  counterparts  treated  with  only  SNAP  or 
CapSNO  (p<0.05)  suggesting  further  deterioration  of 
glucose tolerance. The addition of cysteine to SNAP, or 
CapSNO  increased  postprandial  blood  glucose 
concentration possibly by increasing the efficacy of NO 
release. The effect observed when the RSNOs are co-
administered with cysteine showed that decomposition 
via  the  transnitrosaton  mechanism  can  occur  in  vivo 
using a high concentration of the thiol. In addition the 
result suggests that SNAP was less stable towards this 
type  of  decomposition.  Therefore  the  decomposed 
product,  NO  and  RSNOs  are  responsible  for  the 
observed hyperglycemic effect
[12].  
  Glutathione  (GSH)  is  a  critical  intracellular 
reductant  that  functions  in  protecting  cells  from  free 
radicals, reactive oxygen species and toxic substances. 
The intracellular concentration of GSH is in the range 
of 1-10 mM in many cells and is maintained by controls 
on  its  biosynthesis
[20].  A  number  of  mechanisms  are 
available for transport of cystine or cysteine equivalents 
(cysteinylglycine) into cells. Cysteine can be taken up 
directly  via  the  Na
+-  dependent  amino  acid  transport 
system called the ASC system
[21]. In many cells, this is 
a  major  route  for  supplying  intracellular  cysteine  to 
maintain GSH levels. Rats treated with cysteine showed 
a  hyperglycemic  effect.  S-Nitrosation  of  cysteine 
residues,  resulting  from  the  transfer  of  the  oxidized 
form of NO, to the -SH group of cysteine is another 
important mechanism in NO signaling. This mechanism 
may  result  in  long-lasting  effects  due  to  post-
translational protein modification
[22]. In arteries, protein 
S-nitrosation is increased by exposure to exogenous NO 
or stimulation of endothelial NO synthase activity
[23]. 
The  increased  amount  of  cysteine  administered Am. J. Biochem. & Biotech., 4 (3): 265-272, 2008 
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provides more thiol groups that can be S-nitrosated by 
endogenous and/or exogenous NO with the formation 
of  S-nitrosocysteine.  The  biologically  active  NO 
subsequently  released  from  s-nitrosocysteine  may  be 
responsible for the  hyperglycemic effect observed, as 
this compound has been shown to have a shorter half 
life than CapSNO
[16] and SNAP
[13]. Cysteine was shown 
to  enhance  the  effect  of  SNAP,  which  is  used 
commonly as an NO donor in in vitro experiments with 
intact  cultured  cells.  It  was  suggested  that  cysteine 
could act by promoting transnitrosation from SNAP to 
S-nitrosocysteine, which would be more susceptible to 
intracellular  decomposition,  leading  to  more  effective 
storage or transport of NO within the cell
[9].  
  The hyperglycemic effect of SNAP and CapSNO 
observed  in  the  normoglycemic  rats  could  arise  as  a 
result of a number of factors, including (i) inhibition of 
the  secretory  process  by  NO,  such  that  insufficient 
insulin is secreted in response to a glucose challenge; 
(ii)  a  decrease  in  the  vascular  permeability  of  cell 
membrane by NO, resulting in decreased glucose and 
insulin  delivery  to  the  tissues;  (iii)  the  action  of  NO 
released  from  SNAP  and  CapSNO  on  the  pancreatic 
islet  cells,  impairing  the  first  or  early  phase  of  the 
glucose-stimulated  insulin  release  into  the  blood  and 
(iv) NO inhibition of a number of crucial enzymes in 
the  glycolytic  pathway  and  electron  chain  such  as 
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH) 
and  aconitase  respectively  resulting  in  a  decrease  in 
glycolysis  and  glucose  oxidation
[24].  Of  these 
mechanisms proposed, it is believed that the inhibitory 
effect of NO on GAPDH plays a significant role in the 
observed  hyperglycemic  effect.  S-nitroso-N-
acetylpenicillamine  and  GSNO  have  been  found  to 
inhibit the activity of GAPDH in skeletal muscles of 
type 2 diabetic rats
[25]. Studies have also shown that the 
cysteine residue located at the active site of GAPDH 
(Cys-149) is oxidized by free radicals to a thiyl radical, 
which reacts  with  the  neighboring coenzyme to  form 
Cys-NAD(H) linkages
[26]. Inhibition of GAPDH is due 
primarily to the S-nitrosylation and, to a smaller extent, 
to  the  NAD(H)-  dependent  modification  of  Cys-149. 
SNAP has been found to induce the formation of the 
GAPDH thiyl radical only in the presence of L-cysteine 
and GAPDH thiyl radical was formed by SNAP only in 
the presence of oxygen
[27]. The ability of peroxynitrite 
to  oxidize  protein  thiols  to  thiyl  radicals  has  been 
reported  previously
[27].  However,  this  oxidant  in  its 
anionic form is known to induce further oxidations of 
thiols  to  sulfinic  or  sulfonic  acids
[28].  The 
hyperglycemic effect observed in the rats could be due 
to a lesser extent on the inhibition of aldose reductase in 
the  polyol  pathway  by  NO  released  from  SNAP  and 
CapSNO.  Nitric  oxide  released  from  NO  donors  has 
been  found  to  inhibit  aldose  reductase  in  vascular 
smooth  muscles  by  reversible  S-thiolation  and 
nitrosated  at  Cys-298  at  the  active  site  of  the 
enzyme
[29].  
  The inhibitory effect of NO could also conceivably 
be  exerted  through  the  formation  of  S-nitrosothiols, 
thereby  impairing  thiols  groups  essential  for  insulin 
action.  The  inhibitory  effect  of  intracellular  and 
extracellular  NO  on  insulin  secretory  mechanisms  is 
exerted  through  S-nitrosylation  and  hence  the 
derangement  of  the  reduced/oxidized  glutathione 
balance,  which  previously  has  been  shown  to  be  of 
utmost  importance  for  glucose-induced  insulin 
secretion
[30].  The  evidence  in  favor  of  the  role  of 
exogenous NO in islet cell toxicity includes the lysis of 
islet  cells  in  a  concentration-  and  time-dependent 
manner,  when  they  were  exposed  to  the  NO  donor, 
sodium  nitroprusside  (SNP)
[31].  In  addition,  SNP 
inhibits insulin-stimulated rates of glycogen synthesis at 
concentrations greater than 5 mM in isolated rat soleus 
muscle  preparations
[32].  Experiments  performed  with 
SNAP,  to  validate  the  significance  of  NO  in  the 
development of diabetes, demonstrated cleavage of the 
DNA into nucleosomal fragments. It is proposed that 
internucleosomal DNA cleavage induced by exogenous 
NO activates poly(ADP ribose) synthase, which in turn 
depletes intracellular nicotinamide adenine dinucleotide 
(NAD)  and  causes  poly-ADP-ribosylation  of  nuclear 
proteins,  resulting  in  the  deterioration  of  ￿-cell 
function
[33]. Other supporting evidence includes a study 
done  by  Mosen  and  colleagues  in  which  the 
intracellular  NO  donor  hydroxylamine,  suppressed 
glucose-induced insulin release and enhanced glucagon 
release
[33].  A  possible  mechanism  for  NO-induced 
inhibition  of  glucose-stimulated  insulin  release  is 
exerted through a NO-mediated inactivation of the islet 
lysosomal  enzyme  acid  glucan-1,4-￿-glucosidase 
activity
[34].  
  The excretory form of NO is usually in the form of 
nitrates (NO3
-) and nitrites (NO2
-)
[35] and the conversion 
of  one  form  to  the  next  readily  takes  place  in  vivo. 
However  the  total  nitrite  concentration  incorporates 
both NO2
- and NO3
- species. The results from the total 
nitrite analysis  showed  that  cysteine, or captopril did 
not  cause  a  significant  increase  in  the  NO2
- 
concentration in vivo. This was expected as both thiols 
do  not  contain  a  nitro  group  in  their  structure.  In 
addition  the  probability  of  a  transnitrosation  reaction 
occurring between these thiols and endogenous RSNOs 
is not expected to be significant since the latter group of 
compounds is present at low concentrations
[36] and is 
rapidly  oxidized  to  other  species
[37].  However,  these 
endogenous s-nitroso compounds have been shown to 
be very potent
[38]. A significant increase in total nitrite Am. J. Biochem. & Biotech., 4 (3): 265-272, 2008 
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concentration  was  observed  when  SNAP  or  CapSNO 
were administered. Rats treated with SNAP showed a 
higher  total  nitrite  concentration  than  those 
administered with CapSNO. Therefore SNAP was able 
to decompose more readily in vivo than CapSNO. The 
decomposition of these compounds caused an increase 
in NO concentration which may have been responsible 
for the observed hyperglycemic effect. CapSNO caused 
a significant increase in total nitrite concentration when 
compared  with  saline  treated  rats.  Elevated  levels  of 
plasma nitrate levels, assessed as NO production, were 
observed  in  cysteine  and  CapSNO  treated-rats 
indicating enhanced NO release. This was evident by an 
increase in plasma nitrite concentration. The prolonged 
and  exacerbated  hyperglycemic  effect  in  rats 
administered  with  CapSNO  and  cysteine  could  be 
explained in terms of the fact that exposure of the ￿-
cells  to  increased  NO  levels  resulted  in  further 
deterioration  in  ￿-cell  function  characterized  by 
impairment  in  glucose  metabolism  and  possible 
defective  insulin  response
[39].  To  ensure  that  plasma 
nitrite concentration reliably mirrored NO formation by 
the  constitutive  isoenzyme  nitric  oxide  synthase,  the 
dietary intake of nitrate was standardized, because the 
nitrate  content  of  food  varies  widely.  Dietary  intake 
was standardized by giving each rat a defined diet daily.  
 
CONCLUSION 
 
  In  conclusion,  the  findings  of  this  study  indicate 
that  NO  released  from  SNAP  and  CapSNO  elevated 
postprandial  blood  glucose  and  reduced  glucose 
tolerance in normoglycemic rats. Cysteine exacerbated 
the decreased glucose tolerance by SNAP or CapSNO. 
To our knowledge, this is the report of the detrimental 
effect  of  cysteine  on  glucose  metabolism  in 
normoglycemic rats treated with NO donors and further 
current knowledge on the association of NO donors and 
thiols. An examination of the possible effect of SNAP 
and  cysteine,  or  CapSNO  and  cysteine  on 
glucoregulatory  hormones  in  normoglycemic  or 
diabetic rats is warranted. 
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